利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.026 秒)

    1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
    34.
    发明申请
    1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists 失效
    1-取代的3-吡咯烷衍生物作为毒蕈碱受体拮抗剂

    公开(公告)号：US20060194862A1

    公开(公告)日：2006-08-31

    申请号：US10540245

    申请日：2002-12-23

    申请人： Anita Mehta ,  Jang Gupta ,  Pakala Sarma

    发明人： Anita Mehta ,  Jang Gupta ,  Pakala Sarma

    IPC分类号： A61K31/4025 ,  A61K31/40 ,  C07D405/02 ,  C07D207/04

    CPC分类号： C07D405/12 ,  C07D207/12 ,  C07D207/14

    摘要： This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

    摘要翻译： 本发明一般涉及具有式（I）结构的1-取代-3-吡咯烷二醇衍生物：本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗各种呼吸疾病 ，通过毒蕈碱受体介导的尿路和胃肠道系统。 本发明还涉及制备本发明化合物的方法。 含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

    3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor
    35.
    发明申请
    3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor 失效
    用作毒蕈碱受体的3,6-二取代的氮杂双环[3.1.0]己烷衍生物

    公开(公告)号：US20060142371A1

    公开(公告)日：2006-06-29

    申请号：US10524081

    申请日：2002-08-09

    申请人： Anita Mehta ,  Arundutt Silamkoti ,  Miriyala Bruhaspathy ,  Jang Gupta

    发明人： Anita Mehta ,  Arundutt Silamkoti ,  Miriyala Bruhaspathy ,  Jang Gupta

    IPC分类号： A61K31/403 ,  C07D209/02

    CPC分类号： C07D209/02 ,  C07D209/52

    摘要： This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

    摘要翻译： 本发明一般涉及3,6-二取代的氮杂双环[3.1.0]己烷的衍生物。 本发明的化合物是毒蕈碱受体拮抗剂，其特别用于治疗通过毒蕈碱受体介导的呼吸，尿和胃肠道系统的各种疾病。 本发明还涉及制备本发明化合物的方法，含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

    Flavaxate derivatives as muscarinic receptor antagonists
    36.
    发明申请
    Flavaxate derivatives as muscarinic receptor antagonists 失效
    泛黄酸衍生物作为毒蕈碱受体拮抗剂

    公开(公告)号：US20060128781A1

    公开(公告)日：2006-06-15

    申请号：US10540062

    申请日：2002-12-23

    申请人： Anita Mehta ,  Sanjay Srivastava ,  Jang Gupta

    发明人： Anita Mehta ,  Sanjay Srivastava ,  Jang Gupta

    IPC分类号： A61K31/403 ,  C07D405/02

    CPC分类号： C07D209/52 ,  A61K31/352 ,  C07D405/12

    摘要： This invention generally relates the derivatives of 3.6-disubstituted azabicyclo[3.1.0]hexanes of the following formula [IA]. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the :h1ethods for treating the diseases mediated through muscarinic receptors.

    摘要翻译： 本发明通常涉及下式[IA]的3.6-二取代的氮杂双环[3.1.0]己烷的衍生物。 本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。 本发明还涉及制备本发明化合物的方法，含有本发明化合物的药物组合物和：用于治疗通过毒蕈碱受体介导的疾病的方法。

    Plymorphic forms of phenyl oxazolidinone derivatives
    37.
    发明申请
    Plymorphic forms of phenyl oxazolidinone derivatives 审中-公开
    苯基恶唑烷酮衍生物的多晶型

    公开(公告)号：US20050209248A1

    公开(公告)日：2005-09-22

    申请号：US10514074

    申请日：2003-05-15

    申请人： Biswajit Das ,  Anita Mehta ,  Ashok Rattan

    发明人： Biswajit Das ,  Anita Mehta ,  Ashok Rattan

    IPC分类号： A61K31/496 ,  A61P31/00 ,  A61P31/04 ,  C07D413/12 ,  C07D413/14

    CPC分类号： C07D413/12

    摘要： The invention relates to phenyl oxazolidinone derivatives. More particularly, it relates to polymorphic forms of (S)-N-[[3-fluoro-4-[N-1[4-{2-furyl-(5-nitro)methyl}]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide hydrochloride having the Formula I. Further, the invention relates to methods of using such compounds as antimicrobials, pharmaceutical compositions containing the novel polymorphic forms, and processes for the preparation of the polymorphic forms.

    摘要翻译： 本发明涉及苯基恶唑烷酮衍生物。 更具体地说，它涉及（S）-N - [[3-氟-4- [N-1 [4- {2-呋喃基 - （5-硝基）甲基}]哌嗪基] - 苯基] -2 - 氧代-5-恶唑烷基]甲基]乙酰胺盐酸盐。此外，本发明涉及使用这些化合物作为抗微生物剂的方法，含有新型多晶型物的药物组合物，以及制备多晶型物的方法。

    Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
    38.
    发明授权
    Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells 失效
    使用树突状细胞激活γ/δ-T细胞受体阳性T细胞的方法

    公开(公告)号：US06821778B1

    公开(公告)日：2004-11-23

    申请号：US08610195

    申请日：1996-02-28

    申请人： Edgar G. Engleman ,  Anita Mehta ,  Masaru Takamizawa ,  Francesco Fagnoni ,  Sergiusz Markowicz

    发明人： Edgar G. Engleman ,  Anita Mehta ,  Masaru Takamizawa ,  Francesco Fagnoni ,  Sergiusz Markowicz

    IPC分类号： C12N508

    CPC分类号： C12N5/0636 ,  A61K2039/5158 ,  A61K2039/57

    摘要： This invention relates to methods of using human dendritic cells to present antigens for the induction of antigen-specific T cell-mediated immune responses. In particular, it relates to the isolation of dendritic cells from human blood, exposing the cells to antigens, co-culturing the antigen-pulsed dendritic cells with &ggr;&dgr;-T cell receptor-positive-T cells (&ggr;&dgr;-TCR+ T cells) obtained from unprimed or weakly primed individuals for the stimulation of antigen-specific T cell proliferative and cytotoxic activities. The dendritic cell antigen presentation system described herein has a wide range of applications, including but not limited to, activation and expansion of large numbers of antigen-specific major histocompatibility complex-unrestricted T cells for use in adoptive cellular immunotherapy against infectious diseases and cancer.

    摘要翻译： 本发明涉及使用人树突状细胞呈递抗原以诱导抗原特异性T细胞介导的免疫应答的方法。 特别地，它涉及从人血液中分离树突状细胞，将细胞暴露于抗原，用gammadelta-T细胞受体阳性T细胞（gammadelta-TCR + T细胞）共同培养抗原脉冲的树突状细胞 ）从未引导或弱引发的个体获得，用于刺激抗原特异性T细胞增殖和细胞毒活性。 本文描述的树突状细胞抗原呈递系统具有广泛的应用，包括但不限于大量抗原特异性主要组织相容性复合物无限制T细胞的活化和扩增，用于针对传染病和癌症的过继细胞免疫治疗。